Pfizer Affirms FY2026 Adj EPS Guidance of $2.80-$3.00 vs $2.95 Est; Raises FY2026 Sales Guidance from $59.500B-$62.500B to $60.500B-$62.500B vs $61.793B Est
Pfizer (NYSE:PFE) affirms FY2026 Adj EPS guidance from $2.80-$3.00 to $2.80-$3.00 vs $2.95 analyst estimate. Raises FY2026 sales outlook from $59.500 billion-$62.500 billion to $60.500 billion-$62.500 billion vs $61.793
Pfizer said its profits per share will stay the same, but raised its expected sales forecast a bit—showing the company thinks it'll sell more stuff, though maybe not quite as much as Wall Street hoped.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.